Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)

Abstract Background This study had two aims: to describe patients suffering from first-episode schizophrenia who had stopped taking any antipsychotic medication, and to gain information on the predictors of successful discontinuation. Methods We investigated data from the European First Episode Schi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Schizophrenia research 2016-04, Vol.172 (1-3), p.145-151
Hauptverfasser: Landolt, Karin, Rössler, Wulf, Ajdacic-Gross, Vladeta, Derks, Eske M, Libiger, Jan, Kahn, René S, Fleischhacker, W. Wolfgang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 151
container_issue 1-3
container_start_page 145
container_title Schizophrenia research
container_volume 172
creator Landolt, Karin
Rössler, Wulf
Ajdacic-Gross, Vladeta
Derks, Eske M
Libiger, Jan
Kahn, René S
Fleischhacker, W. Wolfgang
description Abstract Background This study had two aims: to describe patients suffering from first-episode schizophrenia who had stopped taking any antipsychotic medication, and to gain information on the predictors of successful discontinuation. Methods We investigated data from the European First Episode Schizophrenia Trial (EUFEST). From the 325 patients included, 15.7% discontinued all antipsychotic medication. In a first analysis, clinical and sociodemographical predictors of discontinuing any antipsychotic medication were identified, using Cox regression. In the second analysis, logistic regression was used to determine variables associated with those patients who had stopped taking antipsychotic medication and had a favourable outcome, i.e., successful discontinuation. A good outcome was defined as a) having had no relapse within the whole observation period (80.6%), and b) having had no relapse and symptomatic remission at 12-month-follow-up (37.2%). Results Cox regression revealed that a higher proportion of patients from Western European countries and Israel stopped antipsychotic medication than from Central and Eastern European countries, that relapse was associated with discontinuation, and that discontinuers had lower compliance and higher quality of life. Predictors of successful discontinuation differed with the outcome definition used. Using definition b), successful discontinuers had a better baseline prognosis and better baseline social integration. Using definition a), successful discontinuers more often were from Western European countries. Conclusions Region and clinical factors were associated with discontinuation. Prognosis and social integration played an important role in predicting successful discontinuation. As this study had several limitations, for example the observational design regarding discontinuation, further studies are needed to identify predictors of successful discontinuation.
doi_str_mv 10.1016/j.schres.2016.01.046
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1778705002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0920996416300469</els_id><sourcerecordid>1778705002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-62511c1f2912d92c7c387113037bff2b82c09316b79c50ea91f602a954399b293</originalsourceid><addsrcrecordid>eNqFUk2LFDEQDaK44-o_EMlxPXRbSX9kchFkmVVhQWHGc0inq5mMPUmbpBfG3-CPNk2vHrx4ClV5rz7eK0JeMygZsPbdqYzmGDCWPEclsBLq9gnZsEZUBW9APiUbkBwKKdv6iryI8QQArAHxnFzxVnLeNs2G_PoasLcm-RCpH2hvo_EuWTfrZL1bUjqHU7yYo0_W0POCXv-062mcu4g_ZnSJ-jkZf8ZIraPpiHQ3Bz-hdvTOhpjobrLR90j35mh_-ilP7qymh2D1SG923-52-8Pbl-TZoMeIrx7fa5Lzh9tPxf2Xj59vP9wXpt6KVLS8YcywgUvGe8mNMNVWMFZBJbph4N2WG5AVazshTQOoJRta4Fo2dSVlx2V1TW7WulPwefiY1DnvjeOoHfo5KibEVkADwDO0XqEm-BgDDmoK9qzDRTFQiw_qpFYf1OKDAqayD5n25rHD3GXJ_pL-CJ8B71cA5j0fLIZcxaIzWd6AJqne2_91-LeAGa3L3ozf8YLx5OfgsoaKqcgVqP1yC8spsLaCzJfVbxFdsU0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778705002</pqid></control><display><type>article</type><title>Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Landolt, Karin ; Rössler, Wulf ; Ajdacic-Gross, Vladeta ; Derks, Eske M ; Libiger, Jan ; Kahn, René S ; Fleischhacker, W. Wolfgang</creator><creatorcontrib>Landolt, Karin ; Rössler, Wulf ; Ajdacic-Gross, Vladeta ; Derks, Eske M ; Libiger, Jan ; Kahn, René S ; Fleischhacker, W. Wolfgang ; for the EUFEST Study Group ; EUFEST Study Group</creatorcontrib><description>Abstract Background This study had two aims: to describe patients suffering from first-episode schizophrenia who had stopped taking any antipsychotic medication, and to gain information on the predictors of successful discontinuation. Methods We investigated data from the European First Episode Schizophrenia Trial (EUFEST). From the 325 patients included, 15.7% discontinued all antipsychotic medication. In a first analysis, clinical and sociodemographical predictors of discontinuing any antipsychotic medication were identified, using Cox regression. In the second analysis, logistic regression was used to determine variables associated with those patients who had stopped taking antipsychotic medication and had a favourable outcome, i.e., successful discontinuation. A good outcome was defined as a) having had no relapse within the whole observation period (80.6%), and b) having had no relapse and symptomatic remission at 12-month-follow-up (37.2%). Results Cox regression revealed that a higher proportion of patients from Western European countries and Israel stopped antipsychotic medication than from Central and Eastern European countries, that relapse was associated with discontinuation, and that discontinuers had lower compliance and higher quality of life. Predictors of successful discontinuation differed with the outcome definition used. Using definition b), successful discontinuers had a better baseline prognosis and better baseline social integration. Using definition a), successful discontinuers more often were from Western European countries. Conclusions Region and clinical factors were associated with discontinuation. Prognosis and social integration played an important role in predicting successful discontinuation. As this study had several limitations, for example the observational design regarding discontinuation, further studies are needed to identify predictors of successful discontinuation.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2016.01.046</identifier><identifier>PMID: 26922655</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acute Disease ; Adolescent ; Adult ; Antipsychotic Agents - therapeutic use ; Antipsychotic medication ; Europe ; Female ; First episode ; Follow-Up Studies ; Humans ; Interview, Psychological ; Israel ; Logistic Models ; Male ; Patient Dropouts ; Predictors ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Psychiatry ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Young Adult</subject><ispartof>Schizophrenia research, 2016-04, Vol.172 (1-3), p.145-151</ispartof><rights>Elsevier B.V.</rights><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-62511c1f2912d92c7c387113037bff2b82c09316b79c50ea91f602a954399b293</citedby><cites>FETCH-LOGICAL-c487t-62511c1f2912d92c7c387113037bff2b82c09316b79c50ea91f602a954399b293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0920996416300469$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26922655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Landolt, Karin</creatorcontrib><creatorcontrib>Rössler, Wulf</creatorcontrib><creatorcontrib>Ajdacic-Gross, Vladeta</creatorcontrib><creatorcontrib>Derks, Eske M</creatorcontrib><creatorcontrib>Libiger, Jan</creatorcontrib><creatorcontrib>Kahn, René S</creatorcontrib><creatorcontrib>Fleischhacker, W. Wolfgang</creatorcontrib><creatorcontrib>for the EUFEST Study Group</creatorcontrib><creatorcontrib>EUFEST Study Group</creatorcontrib><title>Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>Abstract Background This study had two aims: to describe patients suffering from first-episode schizophrenia who had stopped taking any antipsychotic medication, and to gain information on the predictors of successful discontinuation. Methods We investigated data from the European First Episode Schizophrenia Trial (EUFEST). From the 325 patients included, 15.7% discontinued all antipsychotic medication. In a first analysis, clinical and sociodemographical predictors of discontinuing any antipsychotic medication were identified, using Cox regression. In the second analysis, logistic regression was used to determine variables associated with those patients who had stopped taking antipsychotic medication and had a favourable outcome, i.e., successful discontinuation. A good outcome was defined as a) having had no relapse within the whole observation period (80.6%), and b) having had no relapse and symptomatic remission at 12-month-follow-up (37.2%). Results Cox regression revealed that a higher proportion of patients from Western European countries and Israel stopped antipsychotic medication than from Central and Eastern European countries, that relapse was associated with discontinuation, and that discontinuers had lower compliance and higher quality of life. Predictors of successful discontinuation differed with the outcome definition used. Using definition b), successful discontinuers had a better baseline prognosis and better baseline social integration. Using definition a), successful discontinuers more often were from Western European countries. Conclusions Region and clinical factors were associated with discontinuation. Prognosis and social integration played an important role in predicting successful discontinuation. As this study had several limitations, for example the observational design regarding discontinuation, further studies are needed to identify predictors of successful discontinuation.</description><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic medication</subject><subject>Europe</subject><subject>Female</subject><subject>First episode</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Interview, Psychological</subject><subject>Israel</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Patient Dropouts</subject><subject>Predictors</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Psychiatry</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Young Adult</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUk2LFDEQDaK44-o_EMlxPXRbSX9kchFkmVVhQWHGc0inq5mMPUmbpBfG3-CPNk2vHrx4ClV5rz7eK0JeMygZsPbdqYzmGDCWPEclsBLq9gnZsEZUBW9APiUbkBwKKdv6iryI8QQArAHxnFzxVnLeNs2G_PoasLcm-RCpH2hvo_EuWTfrZL1bUjqHU7yYo0_W0POCXv-062mcu4g_ZnSJ-jkZf8ZIraPpiHQ3Bz-hdvTOhpjobrLR90j35mh_-ilP7qymh2D1SG923-52-8Pbl-TZoMeIrx7fa5Lzh9tPxf2Xj59vP9wXpt6KVLS8YcywgUvGe8mNMNVWMFZBJbph4N2WG5AVazshTQOoJRta4Fo2dSVlx2V1TW7WulPwefiY1DnvjeOoHfo5KibEVkADwDO0XqEm-BgDDmoK9qzDRTFQiw_qpFYf1OKDAqayD5n25rHD3GXJ_pL-CJ8B71cA5j0fLIZcxaIzWd6AJqne2_91-LeAGa3L3ozf8YLx5OfgsoaKqcgVqP1yC8spsLaCzJfVbxFdsU0</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Landolt, Karin</creator><creator>Rössler, Wulf</creator><creator>Ajdacic-Gross, Vladeta</creator><creator>Derks, Eske M</creator><creator>Libiger, Jan</creator><creator>Kahn, René S</creator><creator>Fleischhacker, W. Wolfgang</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)</title><author>Landolt, Karin ; Rössler, Wulf ; Ajdacic-Gross, Vladeta ; Derks, Eske M ; Libiger, Jan ; Kahn, René S ; Fleischhacker, W. Wolfgang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-62511c1f2912d92c7c387113037bff2b82c09316b79c50ea91f602a954399b293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic medication</topic><topic>Europe</topic><topic>Female</topic><topic>First episode</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Interview, Psychological</topic><topic>Israel</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Patient Dropouts</topic><topic>Predictors</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Psychiatry</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Landolt, Karin</creatorcontrib><creatorcontrib>Rössler, Wulf</creatorcontrib><creatorcontrib>Ajdacic-Gross, Vladeta</creatorcontrib><creatorcontrib>Derks, Eske M</creatorcontrib><creatorcontrib>Libiger, Jan</creatorcontrib><creatorcontrib>Kahn, René S</creatorcontrib><creatorcontrib>Fleischhacker, W. Wolfgang</creatorcontrib><creatorcontrib>for the EUFEST Study Group</creatorcontrib><creatorcontrib>EUFEST Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Landolt, Karin</au><au>Rössler, Wulf</au><au>Ajdacic-Gross, Vladeta</au><au>Derks, Eske M</au><au>Libiger, Jan</au><au>Kahn, René S</au><au>Fleischhacker, W. Wolfgang</au><aucorp>for the EUFEST Study Group</aucorp><aucorp>EUFEST Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>172</volume><issue>1-3</issue><spage>145</spage><epage>151</epage><pages>145-151</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>Abstract Background This study had two aims: to describe patients suffering from first-episode schizophrenia who had stopped taking any antipsychotic medication, and to gain information on the predictors of successful discontinuation. Methods We investigated data from the European First Episode Schizophrenia Trial (EUFEST). From the 325 patients included, 15.7% discontinued all antipsychotic medication. In a first analysis, clinical and sociodemographical predictors of discontinuing any antipsychotic medication were identified, using Cox regression. In the second analysis, logistic regression was used to determine variables associated with those patients who had stopped taking antipsychotic medication and had a favourable outcome, i.e., successful discontinuation. A good outcome was defined as a) having had no relapse within the whole observation period (80.6%), and b) having had no relapse and symptomatic remission at 12-month-follow-up (37.2%). Results Cox regression revealed that a higher proportion of patients from Western European countries and Israel stopped antipsychotic medication than from Central and Eastern European countries, that relapse was associated with discontinuation, and that discontinuers had lower compliance and higher quality of life. Predictors of successful discontinuation differed with the outcome definition used. Using definition b), successful discontinuers had a better baseline prognosis and better baseline social integration. Using definition a), successful discontinuers more often were from Western European countries. Conclusions Region and clinical factors were associated with discontinuation. Prognosis and social integration played an important role in predicting successful discontinuation. As this study had several limitations, for example the observational design regarding discontinuation, further studies are needed to identify predictors of successful discontinuation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26922655</pmid><doi>10.1016/j.schres.2016.01.046</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-9964
ispartof Schizophrenia research, 2016-04, Vol.172 (1-3), p.145-151
issn 0920-9964
1573-2509
language eng
recordid cdi_proquest_miscellaneous_1778705002
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acute Disease
Adolescent
Adult
Antipsychotic Agents - therapeutic use
Antipsychotic medication
Europe
Female
First episode
Follow-Up Studies
Humans
Interview, Psychological
Israel
Logistic Models
Male
Patient Dropouts
Predictors
Prognosis
Proportional Hazards Models
Prospective Studies
Psychiatry
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Young Adult
title Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A39%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20discontinuation%20of%20antipsychotic%20medication%20and%20subsequent%20outcomes%20in%20the%20European%20First%20Episode%20Schizophrenia%20Trial%20(EUFEST)&rft.jtitle=Schizophrenia%20research&rft.au=Landolt,%20Karin&rft.aucorp=for%20the%20EUFEST%20Study%20Group&rft.date=2016-04-01&rft.volume=172&rft.issue=1-3&rft.spage=145&rft.epage=151&rft.pages=145-151&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2016.01.046&rft_dat=%3Cproquest_cross%3E1778705002%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778705002&rft_id=info:pmid/26922655&rft_els_id=1_s2_0_S0920996416300469&rfr_iscdi=true